HomeFileStructural heart disease

Structural heart disease

Is the Acceleration Time/Ejection Time Ratio Superior to the Mean Gradient in Predicting Clinical Outcomes After TAVR?

Courtesy of Dr. Juan Manuel Pérez. Traditionally, the mean gradient (MG) has been used to assess post-TAVR outcomes....

Coronary Events after TAVI according to the FRANCE Registry

Between 30% and 70% of patients undergoing transcatheter aortic valve replacement (TAVR) present with coronary artery disease...

Should Early Aortic Valve Replacement Be Indicated in Asymptomatic Severe Aortic Stenosis?

A Meta-Analysis of Randomized Clinical Trials. The management of aortic stenosis in asymptomatic patients remains a matter of...

Predilatation in Self-Expanding Valves

TAVI has become the treatment of choice in specific scenarios. However, predilatation (PRD) remains a matter of...

Tricuspid Regurgitation, TriBicaval Registry

Tricuspid regurgitation (TR) is a condition whose prevalence is expected to increase in the coming years. Surgery...

Edge-To-Edge Treatment with PASCAL: Are There Sex-Specific Differences?

Mitral regurgitation (MR) is a common valve disease associated with heart failure, hospitalizations, and mortality.  In women, it...

ESC 2025 | DOUBLE-CHOICE: Anesthesia Strategies and Self-Expanding Valves in TAVI

TAVI has become the predominant treatment for severe aortic stenosis. The DOUBLE-CHOICE trial analyzed two key aspects:...

Can Colchicine Reduce Post-TAVR Conduction Disturbances?

Courtesy of Dr. Juan Manuel Pérez. Partly caused by perioperative inflammation, conduction disturbances often follow TAVR. Colchicine, known...